# Pizarra — PT-pseudo_4e545d350c5b (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4e545d350c5b
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 22.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.696 ng/mL²
  - PSA velocity: 2.9 ng/mL/yr
  - Prior PSA: 19.9 ng/mL
  - Prostate volume: 31.63 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8591883 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Penicillin (rash)
  - Additional notes: PSA 22 ng/mL. PI-RADS 5. PSAD 0.70. Prostate volume 32 mL. csPCa 0.86.

Vitals: weight 85 kg, height 181 cm, BMI 25.9, BP 120/77 mmHg, HR 64 bpm. Smoking: Ex-smoker (20 pack-yr, quit 2013).

Chief complaint: Persistent prostate-specific antigen elevation alongside recent imaging findings prompted this consultation.

History: Serial prostate-specific antigen measurements demonstrating a steady climb initiated a prolonged urological evaluation for this 68-year-old man. He works as a retired firefighter and resides with his partner, maintaining a brisk pace through weekend hikes. Lower urinary tract complaints surface moderately, yielding an IPSS of 10 driven mainly by occasional hesitancy and mild nocturia. He firmly denies unexplained weight loss, pelvic discomfort, or blood in the urine. Medical background remains clear apart from a distant appendectomy during his twenties and a recent dermatology appointment for actinic keratosis treatment. Former smoking habits total 20 pack-years, though he ceased tobacco use in 2013. Alcohol intake averages nine units each week. Mild visual impairment dictates large-print correspondence, and his adult daughter acts as his main liaison. An autumn 2024 cardiology assessment confirmed steady cardiovascular health without any current prescriptions. Comorbid conditions are absent. Marital status is divorced.

Physical examination: DRE: texture smooth and uniform; mobility intact; no focal nodules or dimensional irregularities detected. The gland measures within normal parameters and presents bilaterally symmetric. General assessment shows stable vital markers and absence of lymphadenopathy or systemic disease indicators. Nutritional status appears robust, and functional mobility remains excellent.

Patient info: retired firefighter; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 9 units / week; exercise Hiking on weekends; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Dermatology — actinic keratosis check.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.89 +/- 0.10   (95% CI 0.62-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.03  (few labelled cases resemble this one)
  - 8.1 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=22.0, age=68.0, psad=0.696, dre_ord=0.0, vol=31.63, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the PSA velocity (2.9 ng/mL/yr) and the prior PSA (19.9 ng/mL), which indicate a significant recent rise, against the PI-RADS 5 and the high csPCa probability (0.8591883). It also missed the context from the PSA history and laboratory panel which might refine the interpretation of the PSA density (0.696 ng/mL²).

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a high probability (0.89) based on limited data. The wide error bar ($\pm 0.10$) suggests high aleatoric uncertainty. A failure mode is that the high csPCa probability (0.86) might be overly weighted if the DRE is reported as 'Normal' and the prior biopsy status is 'None', potentially leading to an overestimation of risk if the MRI findings are equivocal rather than definitive. Another failure mode is ignoring the PSA velocity (2.9 ng/mL/yr), which suggests a more aggressive trajectory than a static PSA value might imply.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <What is the full lab panel, especially relevant markers?> -> <If markers suggest high risk, it would strengthen the biopsy recommendation.>
  <PSA history (trend)> -> <What is the full trend data beyond the headline PSA value?> -> <If the trend is very steep, it would increase the urgency for biopsy.>
  <radiology / mpMRI report> -> <What is the full mpMRI prose?> -> <If the prose strongly suggests clinically significant cancer despite PI-RADS 5, it would strongly support biopsy.>
  <previous GP / urology consultation notes> -> <What were the specific concerns or previous management plans?> -> <If prior notes mention specific LUTS or other findings, it could contextualize the need for biopsy.>

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  Subject: Multiparametric MRI Prostate | Date: 02 Feb 2025 | Facility: Tergooi MC
  Clinical indication: Referral from Dr. N. Kuiper for evaluation of rising PSA (22.0 ng/mL) and prior screening.
  FINDINGS:
  Dimensions of 3.6 x 4.2 x 2.1 cm define the gland, establishing a total volume of 31.63 mL. The transition zone exhibits mild hyperplastic alterations without meaningful urethral compression. A focal abnormality measuring roughly 18 x 14 x 12 mm resides in the right posterior peripheral zone at the base-to-mid level. T2-weighted sequences show marked hypointensity paired with indistinct borders. Restricted diffusion characterizes the diffusion-weighted images, mirrored by low signal on the ADC map. Dynamic contrast studies highlight early, focal enhancement against adjacent tissue. Extracapsular extension and seminal vesicle invasion are absent. Pelvic lymph nodes appear normal. Osseous structures show no suspicious activity.
  IMPRESSION:
  PI-RADS 5 lesion in the right posterior peripheral zone.
  Prostate volume 31.63 mL; PSA density 0.696 ng/mL/mL.
  csPCa predicted probability 0.8591883.

  **PSA history**
  {"date": "Feb 2023", "val": 11.9}
  {"date": "Oct 2023", "val": 15.7}
  {"date": "Jun 2024", "val": 11.7}
  {"date": "Feb 2025", "val": 22.0}

  **laboratory results**
  {"name": "PSA", "val": "22.0 ng/mL", "date": "07 Jan 2025", "flag": "H"}
  {"name": "Free PSA", "val": "4.73 ng/mL", "date": "07 Jan 2025", "flag": ""}
  {"name": "%Free PSA", "val": "21%", "date": "07 Jan 2025", "flag": ""}
  {"name": "Haemoglobin", "val": "15.3 g/dL", "date": "07 Jan 2025", "flag": ""}
  {"name": "WBC", "val": "6.1 x10^9/L", "date": "07 Jan 2025", "flag": ""}
  {"name": "Platelets", "val": "291 x10^9/L", "date": "07 Jan 2025", "flag": ""}
  {"name": "Creatinine", "val": "85 umol/L", "date": "07 Jan 2025", "flag": ""}
  {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "07 Jan 2025", "flag": ""}
  {"name": "Testosterone", "val": "12.4 nmol/L", "date": "07 Jan 2025", "flag": ""}
  {"name": "Alkaline phosphatase", "val": "84 U/L", "date": "07 Jan 2025", "flag": ""}
  {"name": "LDH", "val": "153 U/L", "date": "07 Jan 2025", "flag": ""}

  **previous GP / urology consultation notes**
  {"date": "14 Jun 2024", "author": "Dr. N. Kuiper (GP)", "text": "A PSA reading of 19.9 ng/mL prompted a routine clinical review. We examined the consistent upward trend observed since the first elevation in February 2023 and emphasized the necessity for specialist urological evaluation. Arrangements for a multiparametric MRI and dedicated assessment are now in place."}
  {"date": "15 Feb 2024", "author": "Dr. N. Kuiper (GP)", "text": "Clinical follow-up centered on a PSA measurement of 17.8 ng/mL. Physicians reviewed the progressive climb documented since early 2023, and the patient received counseling on potential clinical implications. Voiding function remains entirely symptom-free."}

NOT RETRIEVED
  get_family_history: Did not call this tool because the retrieval of other documents provided sufficient context regarding the clinical picture and the need for a decision.

WHAT THE EVIDENCE SUPPORTS
  findings that argue FOR sampling this patient now:
  PI-RADS 5 lesion in the right posterior peripheral zone
  PSA velocity of 2.9 ng/mL/yr
  PSA trend shows a significant rise from 11.9 ng/mL (Feb 2023) to 22.0 ng/mL (Feb 2025)
  csPCa predicted probability 0.8591883

  findings that argue AGAINST sampling this patient now:
  DRE findings: Normal
  DRE findings: texture smooth and uniform; mobility intact; no focal nodules or dimensional irregularities detected

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5), the significant PSA velocity, and the steep PSA trend, which aligns with the statistical prior. The normal DRE is a point of contradiction but is often less predictive than high-risk imaging features in this context.

[Sections actually revealed in this consultation: psa_trend, laboratory_results, radiology_report, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging features and aggressive biochemical markers. The PI-RADS 5 lesion in the right posterior peripheral zone, combined with a significant PSA velocity of 2.9 ng/mL/yr and a steep PSA trend from 11.9 ng/mL to 22.0 ng/mL, strongly warrants tissue sampling. Although the DRE was normal, the high-risk imaging and biochemical trajectory override this finding, aligning with the statistical prior.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: psa_trend, laboratory_results, radiology_report, previous_notes
